All In Biotech

Drug Trial Radar · NCT02666157

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study)

Last checked: Nov 20, 2026Latest source record: Feb 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,672 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,672

Planned (sponsor's estimate)

Start

Jan 2016

Primary completion

Dec 2018

Study completion Dec 2018

Sponsor

Lead sponsor
National Cheng-Kung University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tainan Municipal Hospital; E-DA Hospital; National Cheng-Kung University Hospital Dou-Liou Branch; Ministry of Health and Welfare, Taiwan
First posted
Jan 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of warfarin, and might provide a safer, and even more effective and convenient alternative approach to warfarin in non-valvular atrial fibrillation (NVAF), especially in Asians. 2. According to the results of a meta-analysis comparing Asians and non-Asians, NOACs are preferentially indicated in Asians in terms of both efficacy and safety. 3. There is no randomized controlled trial with sufficient power to directly compare the efficacy and safety among NOACs in NVAF, not to speak of Asians and Chinese. 4. Indirect comparisons are only based on observation with a lot of limitations such as heterogeneous background characteristics, difference in study design, and diversity in time within therapeutic range in control group. The findings from indirect comparisons are not conclusive but only hypothesis-generating. 5. This investigator-initiated prospective randomized open blinded end-point clinical trial will directly compare the efficacy and safety among 3 NOACs in patients with NVAF in Taiwan. We hypothesize that rivaroxaban or apixaban is non-inferior to dabigatran in terms of the efficacy.

Conditions

  • Atrial Fibrillation

Interventions

  • Dabigatran etexilateDrug

    this drug is administered twice per day for the entire study period

  • RivaroxabanDrug

    this drug is administered once per day for the entire study period

  • ApixabanDrug

    this drug is administered twice per day for the entire study period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the occurrence of the major embolic eventsTime frame: up to 36 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • National Cheng Kung University Hospital Dou-Liou Branch

    Dou-Liou City, Taiwan · Not yet recruiting

  • E-DA Hospital

    Kaohsiung City, Taiwan · Not yet recruiting

  • Tainan Municipal Hospital

    Tainan, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Tainan City, Taiwan · Recruiting

  • Tainan Hospital Ministry of Health and Welfare

    Tainan, Tainan City, Taiwan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.